Comparison of bypass surgery with drug-eluting stents in diabetic patients with left main coronary stenosis.

PubWeight™: 0.76‹?›

🔗 View Article (PMC 3220255)

Published in Yonsei Med J on November 01, 2011

Authors

Xiaoxiao Zhao1, Yujie Zhou, Hui Song, Like Guan, Guanbin Zheng, Zhehu Jin, Dongmei Shi, Yuzi Li, Yonghe Guo, Guo-Ping Shi, Xian Wu Cheng

Author Affiliations

1: Department of Cardiology, Capital University of Medical Sciences, Beijing, China.

Articles cited by this

Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care (2003) 29.49

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care (1993) 17.66

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17

Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med (2008) 4.96

ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation (2004) 4.49

Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care (1980) 3.70

Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation (2006) 3.22

Multicenter validation of a risk index for mortality, intensive care unit stay, and overall hospital length of stay after cardiac surgery. Steering Committee of the Provincial Adult Cardiac Care Network of Ontario. Circulation (1995) 3.02

Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation (2010) 2.40

ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol (2004) 2.27

Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: A key determinant of survival in diabetics after coronary balloon angioplasty. Circulation (2001) 2.26

Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol (2010) 2.24

Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol (2000) 1.97

Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol (2006) 1.78

Effect of coronary bypass surgery on survival patterns in subsets of patients with left main coronary artery disease. Report of the Collaborative Study in Coronary Artery Surgery (CASS). Am J Cardiol (1981) 1.74

Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation (1995) 1.66

Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation (2002) 1.62

Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol (2005) 1.59

Long-term outcomes of intervention for unprotected left main coronary artery stenosis: coronary stenting vs coronary artery bypass grafting. Circ J (2009) 1.53

Impact of diabetes mellitus on the treatment effect of percutaneous or surgical revascularization for patients with unprotected left main coronary artery disease: a subgroup analysis of the MAIN-COMPARE study. JACC Cardiovasc Interv (2009) 1.43

Impact of the extent of coronary artery disease on outcomes after revascularization for unprotected left main coronary artery stenosis. J Am Coll Cardiol (2010) 1.41

Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol (2010) 1.33

Left main coronary angioplasty: early and late results of 127 acute and elective procedures. Am J Cardiol (1989) 1.19

Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J (2008) 1.11

Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol (2010) 1.09

Elective stenting of unprotected left main coronary artery stenosis: effect of debulking before stenting and intravascular ultrasound guidance. J Am Coll Cardiol (2001) 1.09

Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation (1995) 1.07

Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation (2005) 1.01

Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Am Heart J (2001) 0.97

Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol (2009) 0.96

Comparison of drug-eluting stents versus surgery for unprotected left main coronary artery disease. Am J Cardiol (2007) 0.94

Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients. Am J Cardiol (2007) 0.93

Drug-eluting stent update 2007: part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease). Circulation (2007) 0.91

Technical feasibility, safety, and clinical outcome of stenting of unprotected left main coronary artery bifurcation narrowing. Am J Cardiol (2002) 0.88

Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma. Circulation (1999) 0.88

Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents. Heart (2009) 0.84

Intravascular ultrasound-guided directional coronary atherectomy for unprotected left main coronary stenoses with distal bifurcation involvement. Am J Cardiol (2003) 0.83

Results of percutaneous coronary intervention of the unprotected left main coronary artery in 143 patients and comparison of 30-day mortality to results of coronary artery bypass grafting. Am J Cardiol (2007) 0.83

Results of percutaneous transluminal angioplasty of the left main coronary artery. Am J Cardiol (1991) 0.82

Impact of routine angiographic follow-up after percutaneous coronary drug-eluting stenting for unprotected left main disease: the Turin Registry. Clin Res Cardiol (2010) 0.80

Dobutamine-induced mechanical alternans is a marker of poor prognosis in idiopathic dilated cardiomyopathy. Clin Exp Pharmacol Physiol (2010) 0.80

Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The diabetes and drug eluting stent for LeFT main registry (D-DELFT). EuroIntervention (2008) 0.79

Impact of diabetes mellitus on early and long-term results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease. J Cardiovasc Med (Hagerstown) (2008) 0.78

Do the current ACC/AHA guidelines correctly reflect the attitudes and utilization of PCI in patients with unprotected left main coronary artery stenosis? Catheter Cardiovasc Interv (2005) 0.77

Articles by these authors

Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 3.97

The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature (2008) 3.93

Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med (2007) 2.54

Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.48

A simple method of plaque rupture induction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2006) 2.38

Recruitment of Atg9 to the preautophagosomal structure by Atg11 is essential for selective autophagy in budding yeast. J Cell Biol (2006) 2.35

Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.28

Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation (2007) 2.20

Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation (2008) 2.12

Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation (2009) 2.07

A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet (2011) 2.05

Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension (2006) 2.03

Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest (2007) 2.00

Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology (2013) 1.99

Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem (2005) 1.79

IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe-/- mice. J Clin Invest (2011) 1.77

Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Cardiovasc Res (2012) 1.71

Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res (2011) 1.69

Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice. Arterioscler Thromb Vasc Biol (2008) 1.64

Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population. Atherosclerosis (2011) 1.64

Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis (2005) 1.59

Increased (99m)Tc-sestamibi washout reflects impaired myocardial contractile and relaxation reserve during dobutamine stress due to mitochondrial dysfunction in dilated cardiomyopathy patients. J Am Coll Cardiol (2013) 1.57

Dobutamine stress testing as a diagnostic tool for evaluation of myocardial contractile reserve in asymptomatic or mildly symptomatic patients with dilated cardiomyopathy. JACC Cardiovasc Imaging (2008) 1.56

Enhanced hypertension prevalence in non-Han Chinese minorities from Xinjiang Province, China. Hypertens Res (2009) 1.49

In vivo reconstitution of autophagy in Saccharomyces cerevisiae. J Cell Biol (2008) 1.48

Cathepsin L activity controls adipogenesis and glucose tolerance. Nat Cell Biol (2007) 1.46

Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation (2009) 1.43

Rapamycin affects tissue plasminogen activator and plasminogen activator inhibitor I expression: a potential prothrombotic mechanism of drug-eluting stents. Angiology (2011) 1.42

Impact of transradial coronary procedures on radial artery function. Angiology (2013) 1.41

Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation (2003) 1.35

Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol (2006) 1.35

Prediction of antimicrobial peptides based on sequence alignment and feature selection methods. PLoS One (2011) 1.34

Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res (2005) 1.32

Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation (2007) 1.31

Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J Am Coll Cardiol (2012) 1.31

Identification and quantification of coronary atherosclerotic plaques: a comparison of 64-MDCT and intravascular ultrasound. AJR Am J Roentgenol (2008) 1.26

Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2004) 1.25

Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis (2005) 1.24

Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis (2009) 1.24

Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res (2009) 1.23

Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation (2012) 1.23

Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis. Am J Physiol Heart Circ Physiol (2006) 1.22

Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. PLoS One (2011) 1.15

Exercise training stimulates ischemia-induced neovascularization via phosphatidylinositol 3-kinase/Akt-dependent hypoxia-induced factor-1 alpha reactivation in mice of advanced age. Circulation (2010) 1.14

Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation (2010) 1.11

Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress colocalize with coronary atheromata with thin fibrous caps in pigs. Circulation (2011) 1.11

Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev (2012) 1.11

Cathepsin K deficiency reduces elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol (2011) 1.11

Cathepsin L activity is essential to elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol (2011) 1.09

Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res (2011) 1.09

Mast cell tryptase deficiency attenuates mouse abdominal aortic aneurysm formation. Circ Res (2011) 1.08

Monomeric sarcosine oxidase: role of histidine 269 in catalysis. Biochemistry (2002) 1.08

Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol (2004) 1.07

The immunomodulatory action of sialostatin L on dendritic cells reveals its potential to interfere with autoimmunity. J Immunol (2009) 1.05

Immune activation resulting from NKG2D/ligand interaction promotes atherosclerosis. Circulation (2011) 1.05

Do cathepsins play a role in abdominal aortic aneurysm pathogenesis? Ann N Y Acad Sci (2006) 1.03

Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin Cancer Res (2012) 1.03

Prevalence, awareness, treatment, and control of hypertension among herdsmen living at 4,300 m in Tibet. Am J Hypertens (2012) 1.02

Cystatin C deficiency promotes inflammation in angiotensin II-induced abdominal aortic aneurisms in atherosclerotic mice. Am J Pathol (2010) 1.02

Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction. Diabetes (2012) 1.02

The effects of aqueous extracts prepared from the leaves of Pistacia lentiscus in experimental liver disease. J Ethnopharmacol (2005) 1.02

Osteoarthritic change is delayed in a Ctsk-knockout mouse model of osteoarthritis. Arthritis Rheum (2012) 1.00

A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. J Virol (2012) 1.00

Underuse of medications for chronic diseases in the oldest of community-dwelling older frail Japanese. J Am Geriatr Soc (2006) 0.99

Plasma cathepsin S and cystatin C levels and risk of abdominal aortic aneurysm: a randomized population-based study. PLoS One (2012) 0.99

Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol (2008) 0.99

Cathepsins L and S are not required for activation of dipeptidyl peptidase I (cathepsin C) in mice. Biol Chem (2006) 0.99

Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases. Pharmacol Ther (2011) 0.98

Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men. Clin Endocrinol (Oxf) (2007) 0.98

gamma-Secretase inhibitor reduces diet-induced atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun (2009) 0.98

Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis (2012) 0.97

Deletion of EP4 on bone marrow-derived cells enhances inflammation and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol (2010) 0.97

Matricellular protein CCN3 mitigates abdominal aortic aneurysm. J Clin Invest (2016) 0.96

Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Hypertension (2011) 0.96

Mast cells and metabolic syndrome. Biochim Biophys Acta (2010) 0.95

Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler Thromb Vasc Biol (2011) 0.95

Wnt3a promotes epithelial-mesenchymal transition, migration, and proliferation of lens epithelial cells. Mol Vis (2012) 0.95

Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol (2009) 0.94

Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions. Cardiovasc Res (2010) 0.94

Cutting edge: Deficiency of macrophage migration inhibitory factor impairs murine airway allergic responses. J Immunol (2006) 0.94

Mast cells as mediators and modulators of atherogenesis. Circulation (2007) 0.94

Cell adhesion molecules contribute to Alzheimer's disease: multiple pathway analyses of two genome-wide association studies. J Neurochem (2011) 0.94

Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China. Addict Behav (2012) 0.93

Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3. Am J Pathol (2006) 0.93

Kinetic model for glycan hydrolysis and formation of monosaccharides during dilute acid hydrolysis of sugarcane bagasse. Bioresour Technol (2011) 0.93

CD31: beyond a marker for endothelial cells. Cardiovasc Res (2012) 0.92

Hypothermic injury: the mitochondrial calcium, ATP and ROS love-hate triangle out of balance. Cell Physiol Biochem (2008) 0.92

Cathepsin S deficiency confers protection from neonatal hyperoxia-induced lung injury. Am J Respir Crit Care Med (2007) 0.91

Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterol (2012) 0.91

Arterial baroreflex dysfunction impairs ischemia-induced angiogenesis. J Am Heart Assoc (2014) 0.91

Green tea catechins inhibit the cultured smooth muscle cell invasion through the basement barrier. Atherosclerosis (2003) 0.90

Structural and functional analysis of natrin, a venom protein that targets various ion channels. Biochem Biophys Res Commun (2006) 0.90

Matrix metalloproteinase-2 deficiency impairs aortic atherosclerotic calcification in ApoE-deficient mice. Atherosclerosis (2012) 0.90

Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol (2006) 0.90

Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J Hypertens (2008) 0.90

Biological characteristics of the cerebral venous system and its hemodynamic response to intracranial hypertension. Chin Med J (Engl) (2012) 0.89

Immunoglobulin E and mast cell proteases are potential risk factors of human pre-diabetes and diabetes mellitus. PLoS One (2011) 0.89

The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels. Eur J Endocrinol (2008) 0.89